ArticleWorld journal of surgical oncology2026
Clinical, virological, and immunohistochemical features of laryngeal papilloma with low-risk human papillomavirus infection: insights from a 13-year institutional cohort.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLaryngeal papilloma (LP) is driven primarily by infection with low-risk human papillomavirus (LR-HPV), most often types 6 and 11. However, the clinical relevance of the HPV genotype, viral load, and associated molecular markers in LP remains incompletely understood.
methodsWe retrospectively analyzed 30 patients with LP treated at the University of Ryukyu Hospital between 2010 and 2023. Their tumor samples were subjected to HPV genotyping, viral load quantification, and immunohistochemical profiling (p16, p21, p53, and Ki-67). Correlations of recurrence and remission data with virological and immunohistochemical findings were investigated.
resultsHPV DNA was detected in 28 of the 30 patients (92.9%), with a predominance of HPV-6 (89.3%), and with HPV-11 accounting for 10.7%. HPV-6 subtyping identified 6a, 6b, and 6vc variants. Most lesions were multifocal and localized to the glottis. Surgical resection was performed in 26 patients, among whom the recurrence rate was 87.5%; complete remission was achieved in 34.6% of these patients, more often in younger patients with juvenile-onset and in those with lower Derkay scores. The viral load did not correlate with recurrence or remission. Immunohistochemistry revealed low p16 and p53 expression, while Ki-67 was consistently positive. Of note, p21 was strongly expressed throughout the epithelium in all LP cases with HPV infection, with a significantly greater frequency, than in papillomas at other head and neck sites without LR-HPV infection (p < 0.0001).
conclusionsHPV genotype and viral burden do not predict recurrence or remission of LP. LPs have a unique molecular profile characterized by diffuse p21 expression and high proliferative activity. These findings underscore the need to consider LP as a distinct HPV-driven entity and highlight p21 as a potential biological marker of LR-HPV-associated disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.